DelveInsight’s “Zika Virus Infection Pipeline Insight 2026” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Zika Virus Infection pipeline landscape. It covers the Zika Virus Infection Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Zika Virus Infection Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Zika Virus Infection Pipeline? @ https://www.delveinsight.com/sample-request/zika-virus-infection-pipeline-insight

Key Takeaways from the Zika Virus Infection Pipeline Report

• In March 2026- Cerus Corporation initiated a study RBC unit labels will be indistinguishable for Test and Control products. Medical staff, and others caring for participating patients, as well as the sponsor (and delegates) will be blinded to treatment assignment. Unblinded delegates will monitor the production of the RBC components at designated blood centers.
• DelveInsight’s Zika Virus Infection Pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Zika Virus Infection treatment.
• The leading Zika Virus Infection Companies such as mRNA-1893, GLS-5700, Tyzivumab, INO-A002, TAK-426, EMX-001, Bemcentinib, Niclosamide, Annexin A5, Research Programme: DNA Vaccines, BIT-009 and others.
• Promising Zika Virus Infection Pipeline Therapies such as mRNA-1893, GLS-5700 and others.

Want to know which companies are leading innovation in Zika Virus Infection? @ Zika Virus Infection Clinical Trials Assessment

The Zika Virus Infection Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Zika Virus Infection Pipeline Report also highlights the unmet needs with respect to the Zika Virus Infection.

Zika Virus Infection Overview

Zika fever is a mosquito-borne viral disease caused by Zika virus (ZIKV), consisting of mild fever, rash (mostly maculo-papular), headaches, arthralgia, myalgia, asthenia, and non-purulent conjunctivitis, occurring about two to seven days after the mosquito vector bite. Zika is spread mostly by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). The symptoms typically last for 2-7 days. The diagnosis of the virus is done through a blood test. Zika virus infection during pregnancy can cause infants to be born with microcephaly and other congenital malformations, known as congenital Zika syndrome. Infection with Zika virus is also associated with other complications of pregnancy including preterm birth and miscarriage. Treatment consists of relieving pain, fever, and any other symptom that inconveniences the patient. To prevent dehydration, it is recommended to control the fever, rest, and drink plenty of water.

Zika Virus Infection Emerging Drugs Profile

• mRNA-1893: Moderna Therapeutics

mRNA-1893 contains an mRNA sequence encoding for the structural proteins of the Zika virus and is designed to cause cells to secrete virus-like particles, mimicking the response of the cell after natural infection. The drug is in Phase II clinical studies for the treatment of Zika Virus Infection. In August 2019, Moderna announced that the US FDA has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) for the prevention of Zika virus infection in healthy adults.

• GLS-5700: GeneOne Life Science

GLS-5700 is a DNA vaccine encoding the pre-membrane and envelop (prM-E) proteins of Zika virus (ZIKV). It is being developed by Geneone life science for Zika Virus Infection and is currently in Phase I stage of development.

If you’re tracking ongoing Zika Virus Infection Clinical trials, this press release is a must-read @ Zika Virus Infection Treatment Drugs

The Zika Virus Infection Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Zika Virus Infection with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Zika Virus Infection Treatment.
• Zika Virus Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Zika Virus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Zika Virus Infection market.

Zika Virus Infection Companies

mRNA-1893, GLS-5700, Tyzivumab, INO-A002, TAK-426, EMX-001, Bemcentinib, Niclosamide, Annexin A5, Research Programme: DNA Vaccines, BIT-009 and others.

Zika Virus Infection Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Zika Virus Infection Products have been categorized under various Molecule types such as,

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

From emerging drug candidates to competitive intelligence, the Zika Virus Infection Pipeline Report covers it all @ Zika Virus Infection Market Drivers and Barriers, and Future Perspectives

Scope of the Zika Virus Infection Pipeline Report

• Coverage- Global
• Zika Virus Infection Companies- mRNA-1893, GLS-5700, Tyzivumab, INO-A002, TAK-426, EMX-001, Bemcentinib, Niclosamide, Annexin A5, Research Programme: DNA Vaccines, BIT-009 and others.
• Zika Virus Infection Pipeline Therapies- mRNA-1893, GLS-5700 and others.
• Zika Virus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Zika Virus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Zika Virus Infection Treatment landscape in this detailed analysis @ Zika Virus Infection Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Zika Virus Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Zika Virus Infection – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. mRNA 1893: Moderna Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Tyzivumab: Tychan/WuXi Biologics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. EMX 001: Emergex Vaccines
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Zika Virus Infection Key Companies
21. Zika Virus Infection Key Products
22. Zika Virus Infection- Unmet Needs
23. Zika Virus Infection- Market Drivers and Barriers
24. Zika Virus Infection- Future Perspectives and Conclusion
25. Zika Virus Infection Analyst Views
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/zika-virus-infection-pipeline-insight